MRK dividend yield: 3.25%. DIVO dividend yield: 4.00%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. DIVO is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in DIVO shares.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
DIVO is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in DIVO shares.
Is MRK or DIVO better for dividend income in 2026?
MRK currently offers a 3.25% yield (3.08/share/year) while DIVO offers 4.00% (2.00/share/year). DIVO provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs DIVO earn per year?
With $10,000 invested today: MRK pays approximately $325/year. DIVO pays approximately $400/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $899/year (DIVO).
Does MRK or DIVO pay monthly dividends?
MRK pays quarterly dividends. DIVO pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs DIVO comparison by email
Save your analysis + get weekly dividend insights. Free forever.